Literature DB >> 19820266

Comparing time activity curves using the Akaike information criterion.

Peter Kletting1, Thomas Kull, Sven N Reske, Gerhard Glatting.   

Abstract

The comparison of curves is a common task in many fields of science. Simply comparing the sums of squares or R(2) is not sufficient, and frequently used tests have many disadvantages. The basic idea of the presented method is turning the problem of comparing curves into a problem of model selection using the corrected Akaike Information Criterion. Here, this straightforward approach is applied for comparing curves using the example of (111)In- and (90)Y-labelled anti-CD66 antibody serum time activity data. As a result it is shown that for the investigated (111)In- and (90)Y-labelled anti-CD66 antibodies, the biokinetics between dosimetry and therapy are different with respect to the contribution of the second, longer half-life component. We advocate the use of the presented method rather than employing less advanced approaches for curve comparison.

Mesh:

Substances:

Year:  2009        PMID: 19820266     DOI: 10.1088/0031-9155/54/21/N01

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  8 in total

1.  Systematic deletions in the cellobiohydrolase (CBH) Cel7A from the fungus Trichoderma reesei reveal flexible loops critical for CBH activity.

Authors:  Corinna Schiano-di-Cola; Nanna Røjel; Kenneth Jensen; Jeppe Kari; Trine Holst Sørensen; Kim Borch; Peter Westh
Journal:  J Biol Chem       Date:  2018-12-11       Impact factor: 5.157

2.  Using a single parameter to describe time-activity curves.

Authors:  Cheuk S Kwok; Paul H Frankel; George Lopatin; Lawrence E Williams
Journal:  Cancer Biother Radiopharm       Date:  2014-01-02       Impact factor: 3.099

3.  The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.

Authors:  Andreas Delker; Harun Ilhan; Christian Zach; Julia Brosch; Franz Josef Gildehaus; Sebastian Lehner; Peter Bartenstein; Guido Böning
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

4.  Accuracy of two dosimetry software programs for 177Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms.

Authors:  Keamogetswe Ramonaheng; Johannes A van Staden; Hanlie du Raan
Journal:  Heliyon       Date:  2022-07-06

5.  External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.

Authors:  J Kurth; B J Krause; S M Schwarzenböck; L Stegger; M Schäfers; K Rahbar
Journal:  EJNMMI Res       Date:  2018-04-12       Impact factor: 3.138

6.  EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations.

Authors:  Jonathan I Gear; Maurice G Cox; Johan Gustafsson; Katarina Sjögreen Gleisner; Iain Murray; Gerhard Glatting; Mark Konijnenberg; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-14       Impact factor: 9.236

7.  Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy.

Authors:  Erick Mora-Ramirez; Lore Santoro; Emmanuelle Cassol; Juan C Ocampo-Ramos; Naomi Clayton; Gunjan Kayal; Soufiane Chouaf; Dorian Trauchessec; Jean-Pierre Pouget; Pierre-Olivier Kotzki; Emmanuel Deshayes; Manuel Bardiès
Journal:  Med Phys       Date:  2020-07-31       Impact factor: 4.071

8.  Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.

Authors:  F Guerriero; M E Ferrari; F Botta; F Fioroni; E Grassi; A Versari; A Sarnelli; M Pacilio; E Amato; L Strigari; L Bodei; G Paganelli; M Iori; G Pedroli; M Cremonesi
Journal:  Biomed Res Int       Date:  2013-06-20       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.